The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2022 | Allo-CART and NK therapies in the pipeline for the treatment of hematological malignancies
In this video, Steven Kanner, PhD, Caribou Biosciences, Berkeley, CA, discusses novel therapies, including allogeneic chimeric antigen receptor T-cell (CAR-T) cell and natural killer (NK) cell therapies for the treatment of various hematological malignancies. Dr Kanner first mentions CB-010, which is currently at Phase I clinical trials for patients with lymphoma. This product uses a novel approach of knocking out the PD-1 checkpoint and has shown pre-clinically to result in deeper de-bulking of the tumor. Dr Kanner then gives an overview of another product, CB-012, which is in the pipeline for patients with acute myeloid leukemia (AML) and targets the CD371 protein expressed on AML tumor cells. To conclude, Dr Kanner mentions the excitement around this pre-clinical data and the importance of addressing persistence in CAR-T and NK cell therapies. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
